Assembly Biosciences, Inc. (ASMB) financial statements (2021 and earlier)

Company profile

Business Address 331 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments27415717419421823493
Cash and cash equivalents472534294112054
Short-term investments22713214016417711438
Receivables3333232
Other undisclosed current assets5574233
Total current assets:28316518320122324098
Noncurrent Assets
Operating lease, right-of-use asset121313 
Property, plant and equipment2222111
Long-term investments and receivables      2
Long-term investments      2
Intangible assets, net (including goodwill)42424242424242
Goodwill13131313131313
Intangible assets, net (excluding goodwill)29292929292929
Other noncurrent assets22223  
Other undisclosed noncurrent assets   13 10
Total noncurrent assets:57585858464345
TOTAL ASSETS:340223242259268283142
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities10128101075
Accounts payable23     
Accrued liabilities898101075
Deferred revenue666 
Debt333    
Deferred tax liabilities3322
Other undisclosed current liabilities5 312666
Total current liabilities:24212025181513
Noncurrent Liabilities
Long-term debt and lease obligation91010    
Operating lease, liability91010 
Liabilities, other than long-term debt333637 00 
Deferred revenue313234 
Deferred rent credit    00 
Deferred income tax liabilities333 
Other undisclosed noncurrent liabilities   44393940
Total noncurrent liabilities:42454744393940
Total liabilities:67676769575453
Stockholders' equity
Stockholders' equity attributable to parent27315617519021122989
Common stock0000000
Additional paid in capital713569562559553545384
Accumulated other comprehensive loss(0)(0)(0)(0)(0)(0)(0)
Accumulated deficit(439)(412)(387)(369)(342)(316)(294)
Total stockholders' equity:27315617519021122989
TOTAL LIABILITIES AND EQUITY:340223242259268283142

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Gross profit:5434443
Operating expenses(33)(30)(23)(32)(30)(27)(30)
Operating loss:(29)(26)(20)(28)(26)(23)(27)
Nonoperating income1111110
Investment income, nonoperating    0  
Loss from continuing operations before income taxes:(28)(25)(19)(27)(25)(22)(27)
Income tax expense (benefit)1000(1)00
Net loss available to common stockholders, diluted:(27)(25)(19)(27)(26)(22)(27)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(27)(25)(19)(27)(26)(22)(27)
Other comprehensive loss     (0)(0)
Other undisclosed comprehensive income    0  
Comprehensive loss:(27)(25)(19)(27)(26)(22)(27)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0(0)00(0)00
Comprehensive loss, net of tax, attributable to parent:(27)(25)(18)(27)(26)(22)(27)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: